Pharmacodynamic analysis of the analgesic effect of capsaicin 8% patch (Qutenza™) in diabetic neuropathic pain patients: detection of distinct response groups

Treatment of chronic pain is associated with high variability in the response to pharmacological interventions. A mathematical pharmacodynamic model was developed to quantify the magnitude and onset/offset times of effect of a single capsaicin 8% patch application in the treatment of painful diabetic peripheral neuropathy in 91 patients. In addition, a mixture model was applied to objectively match patterns in pain-associated behavior. The model identified four distinct subgroups that responded differently to treatment: 3.3% of patients (subgroup 1) showed worsening of pain; 31% (subgroup 2) showed no change; 32% (subgroup 3) showed a quick reduction in pain that reached a nadir in week 3, followed by a slow return towards baseline (16% ± 6% pain reduction in week 12); 34% (subgroup 4) showed a quick reduction in pain that persisted (70% ± 5% reduction in week 12). The estimate of the response-onset rate constant, obtained for subgroups 1, 3, and 4, was 0.76 ± 0.12 week−1 (median ± SE), indicating that every 0.91 weeks the pain score reduces or increases by 50% relative to the score of the previous week (= t½). The response-offset rate constant could be determined for subgroup 3 only and was 0.09 ± 0.04 week−1 (t½ 7.8 weeks). The analysis allowed separation of a heterogeneous neuropathic pain population into four homogenous subgroups with distinct behaviors in response to treatment with capsaicin. It is argued that this model-based approach may have added value in analyzing longitudinal chronic pain data and allows optimization of treatment algorithms for patients suffering from chronic pain conditions.

[1]  P. Blumberg,et al.  Vanilloid (Capsaicin) receptors and mechanisms. , 1999, Pharmacological reviews.

[2]  R. Hughes,et al.  Duloxetine for treating painful neuropathy or chronic pain. , 2009, The Cochrane database of systematic reviews.

[3]  J. Ochoa,et al.  Early and late effects of prolonged topical capsaicin on cutaneous sensibility and neurogenic vasodilatation in humans , 1991, Pain.

[4]  M. Nolano,et al.  Topical capsaicin in humans: parallel loss of epidermal nerve fibers and pain sensation , 1999, Pain.

[5]  L. Webster,et al.  Efficacy, safety, and tolerability of NGX-4010, capsaicin 8% patch, in an open-label study of patients with peripheral neuropathic pain. , 2011, Diabetes research and clinical practice.

[6]  J. Ochoa,et al.  Early and Late Effects of Prolonged Topical Capsaicin on Cutaneous Sensibility and Neurogenic Vasodilation in Humans , 1992 .

[7]  M. Koltzenburg Painful neuropathies. , 1998, Current opinion in neurology.

[8]  S. Abram Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch , 2012 .

[9]  A. Basbaum,et al.  The Cloned Capsaicin Receptor Integrates Multiple Pain-Producing Stimuli , 1998, Neuron.

[10]  D. Howes Sensation , 2011, The Drama of Celebrity.

[11]  R. Baron,et al.  262 A CROSS‐SECTIONAL SURVEY IN 2100 PATIENTS WITH PAINFUL DIABETIC NEUROPATHY AND POSTHERPETIC NEURALGIA: DIFFERENCES IN DEMOGRAPHIC DATA AND SENSORY SYMPTOMS , 2010 .

[12]  P. Wiffen,et al.  Pregabalin for acute and chronic pain in adults. , 2009, The Cochrane database of systematic reviews.

[13]  P. Dyck,et al.  Pathologic Alterations in the Diabetic Neuropathies of Humans: A Review , 1996, Journal of neuropathology and experimental neurology.

[14]  A. Beydoun,et al.  Gabapentin for the Symptomatic Treatment of Painful Neuropathy in Patients With Diabetes Mellitus: a Randomized Controlled Trial , 1999 .

[15]  P. Wiffen,et al.  Gabapentin for chronic neuropathic pain and fibromyalgia in adults. , 2011, The Cochrane database of systematic reviews.

[16]  D. Julius,et al.  The capsaicin receptor: a heat-activated ion channel in the pain pathway , 1997, Nature.

[17]  D. Ranoux [Painful peripheral neuropathy]. , 2008, La Revue du praticien.

[18]  Marieke Niesters,et al.  Population pharmacokinetic—pharmacodynamic modeling of ketamine‐induced pain relief of chronic pain , 2011, European journal of pain.

[19]  Manfred Morari,et al.  The Well-being Model: A New Drug Interaction Model for Positive and Negative Effects , 2006, Anesthesiology.

[20]  J. Potter,et al.  The pathogenesis and management of painful diabetic neuropathy: a review , 2003, Diabetic medicine : a journal of the British Diabetic Association.

[21]  A. Vinik Advances in diabetes for the millennium: new treatments for diabetic neuropathies. , 2004, MedGenMed : Medscape general medicine.

[22]  J. Marinus,et al.  Ketamine produces effective and long-term pain relief in patients with Complex Regional Pain Syndrome Type 1 , 2009, PAIN.

[23]  Erik Olofsen,et al.  Pharmacokinetic–Pharmacodynamic Modeling of the Effectiveness and Safety of Buprenorphine and Fentanyl in Rats , 2007, Pharmaceutical Research.

[24]  Ralf Baron,et al.  A cross-sectional cohort survey in 2100 patients with painful diabetic neuropathy and postherpetic neuralgia: Differences in demographic data and sensory symptoms , 2009, PAIN.